BMRN endpoints article.revisiting KOL comments on BMRN bleed free vs. FVIII % data | SGMO Message Board Posts


Sangamo Therapeutics, Inc.

  SGMO website

SGMO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  168027 of 170018  at  10/2/2022 10:41:36 AM  by

NHangel


 In response to msg 168023 by  ZFP
view thread

Re:BMRN endpoints article.revisiting KOL comments on BMRN bleed free vs. FVIII % data

Big difference in granularity and frequency of trial data releases is that PFE is a big pharma and such releases are approximately immaterial to its profitability and capitalization. For smaller pharma, early data (at least before the bio bear market) could be market moving and have impact on capital availability, even survival.


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 7  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
168028 Re:BMRN endpoints article.revisiting KOL comments on BMRN bleed free vs. FVIII % data nocashonhand 0 10/2/2022 10:47:57 AM
168029 Re:BMRN endpoints article.revisiting KOL comments on BMRN bleed free vs. FVIII % data rynotheknife 0 10/2/2022 11:19:34 AM




Financial Market Data provided by
.
Loading...